Precision Biologics Introduces Monoclonal Antibody PB-223
Precision Biologics is excited to announce the presentation of their novel monoclonal antibody, PB-223, at the Society for Immunotherapy of Cancer's (SITC) upcoming Annual Meeting. This mAb specifically targets the anti-human carcinoma O-glycan epitope, showcasing innovative research in cancer treatments.
Key Presentation Dates and Details
The details surrounding the presentation of mAb PB-223 will be prominently featured during the SITC Annual Meeting, slated for November. This significant event marks a pivotal moment for Precision Biologics in sharing its findings with industry professionals and advocates.
Presentation Schedule
The poster presentations include valuable insights into the new developments:
- November 7, 2024: SITC Immune Engineering Workshop, from 3:10 PM to 5:00 PM CST.
- November 8, 2024: Poster Session on Immuno-Engineering, with presentations scheduled at 12:15 PM–1:45 PM CST and 5:30 PM–7:00 PM CST.
Unique Characteristics of PB-223
PB-223 is an exciting new development in monoclonal antibody therapy. Engineering efforts focused on enhancing binding affinity, which traditionally can impede therapeutic efficacy in clinical applications. By employing the Fast Screening for Expression Biophysical Properties and Affinity method, Precision Biologics successfully refined the VH and VL sequences from the original NEO-102 antibody.
Research Findings
The research demonstrates that PB-223 shows a reduced KD (dissociation constant) compared to NEO-102, indicating a significantly higher binding capability to target antigens. Flow cytometry analysis shows exceptional binding potential not only to recognized cell lines but also to new tumor lines.
Implications for Cancer Therapy
The implications of these findings are profound. PB-223's focused targeting may provide an avenue for developing effective antibody-drug conjugates (ADCs), which can lead to enhanced treatment options for various human carcinomas. Immunohistochemistry analysis further reinforces that PB-223 differentiates well between tumor and healthy tissues, fulfilling a crucial need in oncology drug development.
Conclusion
The advancements made with PB-223 represent a robust contribution to the ongoing efforts in cancer therapeutics. This research underscores the potential of monoclonal antibodies in providing targeted cancer treatments while minimizing the impact on healthy tissues. The upcoming presentation at SITC will unveil critical insights into this promising drug candidate.
Frequently Asked Questions
What is PB-223?
PB-223 is a novel monoclonal antibody specifically designed to target anti-human carcinoma O-glycan epitopes, representing innovative research in cancer treatment.
Where will the presentation of PB-223 take place?
The presentation will be at the Society for Immunotherapy of Cancer's Annual Meeting, featuring poster sessions focused on its development.
What is the significance of the new binding affinity of PB-223?
The increased binding affinity allows PB-223 to more effectively target cancer cells, suggesting its potential in improving therapeutic outcomes.
How does PB-223 differentiate from NEO-102?
PB-223 has shown a markedly improved binding affinity compared to NEO-102, enhancing its effectiveness against various cancer cell lines.
What potential does PB-223 have for future treatments?
The findings suggest that PB-223 could lead to the development of effective antibody-drug conjugates for multiple forms of cancer, improving targeted therapy options.
